Chemotherapy: Volume 8 Cancer Chemotherapy IIKurt Hellmann The International Society of Chemotherapy meets every two years to review progress in chemotherapy of infections and of malignant disease. Each meeting gets larger to encompass the extension of chemotherapy into new areas. In some instances, exp~sion has been rapid, for example in cephalosporins, pen icillins and combination chemotherapy of cancer - in others slow, as in the field of parasitology. New problems of resistance and untoward effects arise; reduction of host toxicity without loss of antitumour activity by new substances occupies wide attention. The improved results with cancer chemotherapy, es pecially in leukaemias, are leading to a greater prevalence of severe infection in patients so treated, pharmacokinetics of drugs in normal and diseased subjects is rece1v1ng increasing attention along with related problems of bioavailability and interactions between drugs. Meanwhile the attack on some of the major bacterial infections, such as gonorrhoea and tubercu losis, which were among the first infections to feel the impact of chemotherapy, still continue to be major world problems and are now under attack with new agents and new methods. From this wide field and the 1,000 papers read at the Congress we have produced Proceedings which reflect the variety and vigour of research in this important field of medicine. It was not possible to include all of the papers presented at the Congress but we have attempted to include most aspects of cur rent progress in chemotherapy. |
Contents
On the Cytogenetic Criteria of Rational Tumor | 1 |
Breakdown of NonImmune Metastasis Resistance after | 9 |
Effects of AntiDNA and AntiRNA Antibodies Bound | 17 |
Copyright | |
69 other sections not shown
Common terms and phrases
1xday i. p. 5-fluorouracil acid activity administration Adriamycin agents alkylating animals antibiotic antibody anticancer antigen antitumour ARA-C ascites BCNU bleomycin blood caffeine Cancer Chemotherapy cancer patients carcinoma carminomycin CCNU chemotherapeutic chromosomal cis Pt(II clinical combination chemotherapy complete remission compounds cycle cyclophosphamide cytostatic Damvar daunorubicin decrease disease dosage dose drug effect enzyme evaluation Figure fraction growth histones immune immunosuppressive immunotherapy increase inhibition injection inoculation intraperitoneally intravenous irradiation large-dose leukaemia levamisole liver lung lymphocytes lymphoma lysosomal malignant mean survival melanoma Melphalan metabolites metastases method Methotrexate mg/kg mg/kg/inj mice Mimosine Mitomycin months nitrosourea normal observed obtained patients treated Peptichemio phase phenobarbital pretreated proteins radioactivity radiotherapy rats regimen regression response sarcoma sensitive serum showed spleen Surgery Table therapeutic therapy Tilorone tissue toxicity transplantable treatment tumor tumor cells variamycin Vincristine vitro vivo weeks Yoshida